GABA and brain abnormalities in schizophrenia.

Some recent autopsy studies indicate that gamma-aminobutyric acid (GABA) function is decreased in brain areas that involve some of the well-described structural changes observed in schizophrenia. The current study examined the relationship between CSF and plasma GABA levels and brain structural measures in schizophrenia. Sixty-two drug-free, physically healthy male patients with schizophrenia (DSM-IIIR) were evaluated for plasma and CSF GABA, as well as brain structural measures on CT scans. Plasma levels of GABA were associated with prefrontal sulcal widening and VBRs, but not global sulcal widening in the schizophrenic patients. CSF GABA measures were not associated with brain structural measures, but were associated with age and age of onset. The significant relationship between plasma GABA, but not CSF GABA, and specific brain morphology measures in schizophrenic patients suggests that if GABA transmission is impaired in schizophrenia, it is a local, but not global, phenomenon.

Utility of WAIS-R short forms in schizophrenia.

Recently, short forms of the Wechsler Adult Intelligence Scale-Revised (Wechsler, 1981) have received increasing attention because of their ability to provide estimated IQ scores with substantial time savings (in some cases 85-90% savings). These short forms may have particular utility for individuals with schizophrenia because they require less time to administer and, as a result, are less taxing for these patients who often exhibit impaired attention and deficient motivation. In this study, we examine the psychometric properties of nine popular WAIS-R short forms in a group of 143 patients diagnosed with schizophrenia. Our results indicated that Kaufman's four subtest short form was the best overall estimator of Full Scale IQ (FSIQ) when a combination of administration time and psychometric properties were considered. However, Ward's seven subtest short form provided the closest estimation of FSIQ and had the lowest misclassification rate, while also providing estimates of Verbal and Performance IQs and yielding 46.5-49.7% time savings. All short forms had substantial misclassification rates, indicating that caution is warranted when using these forms to classify individuals according to standard levels of intellectual functioning (e.g., Average, Low Average, High Average). Clearly, the main consideration in selecting a short form is whether time savings or accuracy have priority.

Chronic haloperidol treatment does not affect structure of attention in schizophrenia.

Results of a number of investigations indicate attention is a multifactorial construct composed of four distinct cognitive factors including focus-execute, sustain, encode and shift abilities. While investigators have partially or fully replicated this attentional structure in a number of clinical and nonclinical populations, no study has adequately examined the structure of attention in patients with schizophrenia who are not treated with antipsychotics. In this study, we examined the four-factor theory of attention in patients with schizophrenia while they were stabilized on haloperidol (with no adjunctive antiparkinsonian/anticholinergic medications) and again when they were approximately 3 weeks drug free. Standard neuropsychological measures were used to assess attentional functions. Principal components analyses (varimax rotation) of neuropsychological test scores in medicated and drug-free conditions indicated that four factors accounted for 84.2 and 91.8 of total variance in medicated and unmedicated conditions, respectively. Based on these results, it appears that: (1) haloperidol does not appreciably affect structure of the attentional system in patients with schizophrenia; (2) unmedicated patients with schizophrenia exhibit a similar structure of attention as both medicated patients and controls, suggesting that attentional structure is 'normal' in schizophrenia; and (3) the four-factor attention theory is a useful and valid paradigm for evaluating attention in patients with schizophrenia, regardless of medication status.

Protein modifications by activated carcinogens. II. The acetylation of ribonuclease by N-acetoxy-3-fluorenylacetamide.

The reaction of N-[3H]acetoxy-3-fluorenylacetamide (N-[3H]acetoxy-3-FAA), a potent carcinogen for the rat, with RNAase yielded three modified proteins separable from RNAase by ion exchange chromatography on Bio-Gel CM-30 with a gradient of increasing sodium ion concentration. Only minor amounts of RNAase were recovered. The modified proteins were labeled with 3H to a varying degree, and their order of elution was inversely related to the extent of labeling. The modification of the proteins was the result of the transfer of the acetyl group from N-[3H]acetoxy-3-FAA to RNAase. The evidence for this conclusion was (a) the release of 84-86% of the radioactivity as [3H] acetic acid from the two major proteins upon acid hydrolysis and (b) the isolation of eplision-N-[3H] acetyl-L-lysine from enzymatic hydrolysates of these proteins. A comparison of the present data with those previously reported for the acetylaton of RNAase by the isomeric carcinogen, N-acetoxy-2-FAA, showed that N-acetoxy-3-FAA is the more potent acetyl-lating agent. The present study in conjunction with the previous results, suggests that structural alteration of cellular nucleopholes by acylation may be a biochemical mechanism underlying the biological activity of N-acetoxy-3-FAA and related activated carcinogens.